Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aptevo Therapeutics Q3 EPS $(2.23) Misses $(2.09) Estimate

Author: Benzinga Newsdesk | November 06, 2025 08:37am
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(2.09) by 6.7 percent. This is a 99.38 percent increase over losses of $(357.86) per share from the same period last year.

Posted In: APVO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist